Pan-cancer (pan-cancer/NSCLC models; cross-indication) evidence suggests enhanced ICI sensitivity with TSC1/2 alterations, informing mTOR- and ICI-based strategies [115]. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.